424870 — ImmuneOncia therapeutics Balance Sheet
0.000.00%
Last trade - 00:00- KR₩458bn
- KR₩420bn
- KR₩655m
Annual balance sheet for ImmuneOncia therapeutics, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | |
|---|---|---|
| Period Length: | — | — |
| Source: | PROSPECTUS | PROSPECTUS |
| Standards: | IFRS | IFRS |
| Status: | Final | Final |
| Cash and Equivalents | ||
| Short Term Investments | ||
| Cash and Short Term Investments | 25,957 | 11,326 |
| Net Total Accounts Receivable | ||
| Net Total Receivables | 302 | 8,239 |
| Prepaid Expenses | ||
| Total Current Assets | 26,636 | 19,863 |
| Gross Property, Plant And Equipment | ||
| Accumulated Depreciation | ||
| Net Property, Plant And Equipment | 892 | 495 |
| Net Intangible Assets | ||
| Other Long Term Assets | ||
| Total Assets | 33,795 | 26,195 |
| Accrued Expenses | ||
| Notes Payable / Short Term Debt | ||
| Current Portion of Long Term Debt / Capital Leases | ||
| Total Other Current Liabilities | ||
| Total Current Liabilities | 67,650 | 6,493 |
| Capital Lease Obligations | ||
| Total Long Term Debt | ||
| Total Debt | ||
| Total Other Liabilities | ||
| Total Funded Status | ||
| Total Liabilities | 67,987 | 6,771 |
| Common Stock | ||
| Additional Paid In Capital | ||
| Retained Earnings (Accumulated Deficit) | ||
| ESOP Debt Guarantee | ||
| Other Equity | ||
| Total Equity | -34,192 | 19,424 |
| Total Liabilities & Shareholders' Equity | 33,795 | 26,195 |
| Total Common Shares Outstanding |